Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta...
12 insider purchases on record · latest filing 2026-03-10.
Insiders have also filed 112 sale transactions at VKTX.